A Model of Placebo Response in Antidepressant Clinical Trials
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Placebo response in clinical trials of antidepressant medications is substantial and has been increasing. High placebo response rates hamper efforts to detect signals of efficacy for new antidepressant medications, contributing to trial failures and delaying the delivery of new treatments to market. Media reports seize upon increasing placebo response and modest advantages for active drugs as reasons to question the value of antidepressant medication, which may further stigmatize treatments for depression and dissuade patients from accessing mental health care. Conversely, enhancing the factors responsible for placebo response may represent a strategy for improving available treatments for major depressive disorder. A conceptual framework describing the causes of placebo response is needed in order to develop strategies for minimizing placebo response in clinical trials, maximizing placebo response in clinical practice, and talking with depressed patients about the risks and benefits of antidepressant medications. In this review, the authors examine contributors to placebo response in antidepressant clinical trials and propose an explanatory model. Research aimed at reducing placebo response should focus on limiting patient expectancy and the intensity of therapeutic contact in antidepressant clinical trials, while the optimal strategy in clinical practice may be to combine active medication with a presentation and level of therapeutic contact designed to enhance treatment response.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are several potential explanations, as many factors have been associated with higher placebo response rates, such as randomisation ratio and the expectation of receiving an active treatment, the therapeutic setting, or the frequency of study visits.24”
In the citing paper
“Late-life depression (LLD) is a common and debilitating condition, with less frequent remission and more frequent recurrence following first-line antidepressant treatment compared to depression experienced earlier in life1–7.”
From Psychobiological factors of resilience and depression in late life (2019) · cites this paper as [5]
In the citing paper
“Whilst previous meta-analyses have demonstrated that control group responses (CGRs) can negatively influence antidepressant efficacy”
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Measurement and Control of Response Bias
Paulhus, D. L. (1991) · Measures of Personality and Social Psychological Attitudes · doi:10.1016/b978-0-12-590241-0.50006-x · Cited by 3,598
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Regression to the mean: what it is and how to deal with it
Barnett, A. G. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh299 · Cited by 1,988 · cited 1×
“One source of apparent symptom change in antidepressant trials is regression to the mean, which is a statistical phenomenon occurring when repeated measurements associated with random error are made on the same subject over time (32).”
BackgroundPlacebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“In antidepressant trials for adults, placebo response averages 31% compared to a mean medication response of 50%, and it has risen at a rate of 7% per decade over the past 30 years (1).”
BackgroundThe Functional Neuroanatomy of the Placebo Effect
Mayberg, H. S., Silva, J. A., Brannan, S. K., Tekell, J. L., Mahurin, R. K., McGinnis, S., & Jerabek, P. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.728 · Cited by 720
The Placebo Effect: Dissolving the Expectancy Versus Conditioning Debate.
Stewart-Williams, S., & Podd, J. (2004) · Psychological Bulletin · doi:10.1037/0033-2909.130.2.324 · Cited by 664
Lespérance, F., Frasure-Smith, N., Koszycki, D., Laliberté, M.-A., van Zyl, L. T., Baker, B., Swenson, J. R., Ghatavi, K., Abramson, B. L., Dorian, P., et al. (2007) · JAMA · doi:10.1001/jama.297.4.367 · Cited by 658
Newcome, F. (1968) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.31.4.409-c · Cited by 629
Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication.
Kirsch, I., & Sapirstein, G. (1998) · Prevention & Treatment · doi:10.1037/1522-3736.1.1.12a · Cited by 502
Petrovic, P., Dietrich, T., Fransson, P., Andersson, J., Carlsson, K., & Ingvar, M. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.023 · Cited by 437 · cited 1×
“Functional magnetic resonance imaging (fMRI) studies of expectancy-based placebo effects have provided converging evidence suggesting that the brain areas associated with generating and maintaining expectancies comprise prefrontal cortex subregions, orbitofrontal cortex, and the rostral anterior cingulate cortex (67).”
BackgroundNegative effects from psychological treatments: a perspective
Barlow, D. H. (2010) · American Psychologist · doi:10.1037/a0015643 · Cited by 426
Mechanisms of Placebo and Placebo-Related Effects Across Diseases and Treatments
Benedetti, F. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094711 · Cited by 385
Personality Change During Depression Treatment: A Placebo-Controlled Trial
Tang, T. Z., DeRubeis, R. J., Hollon, S. D., Amsterdam, J., Shelton, R., & Schalet, B. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.166 · Cited by 384 · cited 1×
“, decreased neuroticism) compared to cognitive therapy or placebo (66).”
BackgroundPapakostas, G. I., & Fava, M. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.08.009 · Cited by 382
Benedetti, F., Arduino, C., Costa, S., Vighetti, S., Tarenzi, L., Rainero, I., & Asteggiano, G. (2006) · Pain · doi:10.1016/j.pain.2005.12.016 · Cited by 347
Changing expectations: a key to effective psychotherapy
(1990) · Choice Reviews Online · doi:10.5860/choice.28-2424 · Cited by 346
Meta-analysis of the placebo response in antidepressant trials.
Rief, W., Nestoriuc, Y., Weiss, S., Welzel, E., Barsky, A. J., & Hofmann, S. G. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.029 · Cited by 346
Meyer, B., Pilkonis, P. A., Krupnick, J. L., Egan, M. K., Simmens, S. J., & Sotsky, S. M. (2002) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.70.4.1051 · Cited by 322
Cost-effectiveness of Treatments for Major Depression in Primary Care Practice
Lave, J. R., Frank, R. G., Schulberg, H. C., & Kamlet, M. S. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.645 · Cited by 306
Long-term Outcome of Episodes of Major Depression: Clinical and Public Health Significance
Keller, M. B. (1984) · JAMA · doi:10.1001/jama.252.6.788 · Cited by 295
Bridge, J. A., Birmaher, B., Iyengar, S., Barbe, R. P., & Brent, D. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020247 · Cited by 256 · cited 2×
“Children and adolescents with Major Depressive Disorder exhibit even higher rates of placebo response (mean of 46% compared to a mean medication response of 59%) that have also been increasing over time (2).”
BackgroundZung, Beck and Hamilton Rating Scales as measures of treatment outcome: a meta-analytic comparison.
Lambert, M. J., Hatch, D. R., Kingston, M. D., & Edwards, B. C. (1986) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.54.1.54 · Cited by 232
Delusional Depression: A Distinct Clinical Entity?
Glassman, A. H. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780290058006 · Cited by 227
Roose, S. P., Sackeim, H. A., Krishnan, K. R. R., Pollock, B. G., Alexopoulos, G., Lavretsky, H., Katz, I. R., Hakkarainen, H., & Old-Old Depression Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.2050 · Cited by 191
Self-citationSinyor, M., Levitt, A. J., Cheung, A. H., Schaffer, A., Kiss, A., Dowlati, Y., & Lanctôt, K. L. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04516blu · Cited by 189
Mojtabai, R., & Olfson, M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0704 · Cited by 185
Does a Placebo Run-In or a Placebo Treatment Cell Affect the Efficacy of Antidepressant Medications?
Trivedi, M. H., & Rush, J. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.63 · Cited by 175
The physician's actions and the outcome of illness in family practice.
Bass, M. J., Buck, C., Turner, L., Dickie, G. L., Pratt, G. A., & Robinson, H. (1986) · PubMed · Cited by 167
A meta-analysis of antidepressant outcome under "blinder" conditions.
Greenberg, R. P., Bornstein, R. F., Greenberg, M. D., & Fisher, S. (1992) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.60.5.664 · Cited by 164
Does Study Design Influence Outcome?
Rutherford, B. R., Sneed, J. R., & Roose, S. P. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000209348 · Cited by 158
Self-citationPosternak, M. A., & Zimmerman, M. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.028555 · Cited by 154
Sneed, J. R., Rutherford, B. R., Rindskopf, D., Lane, D. T., Sackeim, H. A., & Roose, S. P. (2008) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181256b1d · Cited by 140
Self-citationAre drug and placebo effects in depression additive?
Kirsch, I. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00832-5 · Cited by 137
Are placebo controls necessary to test new antidepressants and anxiolytics?
Khan, A., Khan, S., & Brown, W. A. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002912 · Cited by 130
Stein, D. J., Baldwin, D. S., Dolberg, O. T., Despiegel, N., & Bandelow, B. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1111 · Cited by 120
Gueorguieva, R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.132 · Cited by 115
Kobak, K. A., Kane, J. M., Thase, M. E., & Nierenberg, A. A. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802eb4b7 · Cited by 113
Krell, H. V., Leuchter, A. F., Morgan, M., Cook, I. A., & Abrams, M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0904 · Cited by 109
Frequency of Provider Contact After FDA Advisory on Risk of Pediatric Suicidality With SSRIs
Morrato, E. H., Libby, A. M., Orton, H. D., deGruy, F. V., Brent, D. A., Allen, R., & Valuck, R. J. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010205 · Cited by 100
Nutt, D., & Goodwin, G. M. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.05.004 · Cited by 99
Khan, A., Kolts, R. L., Thase, M. E., Krishnan, K. R. R., & Brown, W. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.2045 · Cited by 94
Muthén, B., & Brown, H. C. (2009) · Statistics in Medicine · doi:10.1002/sim.3721 · Cited by 86
Contribution of spontaneous improvement to placebo response in depression: A meta-analytic review
Rutherford, B. R., Mori, S., Sneed, J. R., Pimontel, M. A., & Roose, S. P. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.02.008 · Cited by 79 · cited 1×
“5) over a mean follow up duration of 10 weeks (44).”
BackgroundSelf-citationKhan, A., Bhat, A., Kolts, R., Thase, M. E., & Brown, W. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00151.x · Cited by 78
Kisely, S., Scott, A., Denney, J., & Simon, G. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.019869 · Cited by 77
The Double-Blind Variable Placebo Lead-in Period: Results From Two Antidepressant Clinical Trials
Faries, D. E., Heiligenstein, J. H., Tollefson, G. D., & Potter, W. Z. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200112000-00004 · Cited by 76
Context Effects: Powerful Therapies or Methodological Bias?
Blasi, Z. D., & Kleijnen, J. (2003) · Evaluation & the Health Professions · doi:10.1177/0163278703026002003 · Cited by 75
The persistence of the placebo response in antidepressant clinical trials
Khan, A., Redding, N., & Brown, W. A. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.10.004 · Cited by 72
Domino, M. E., Foster, E. M., Vitiello, B., Kratochvil, C. J., Burns, B. J., Silva, S. G., Reinecke, M. A., & March, J. S. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181a2b319 · Cited by 71
Thase, M. E., Larsen, K. G., & Kennedy, S. H. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.093336 · Cited by 71
The Impact of Restrictive Entry Criterion During the Placebo Lead‐in Period
Landin, R., DeBrota, D. J., DeVries, T. A., Potter, W. Z., & Demitrack, M. A. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00271.x · Cited by 57
Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication.
Sapirstein, G. (1998) · Prevention & Treatment · doi:10.1037//1522-3736.1.0002a · Cited by 56
Interrater Reliability in Clinical Trials of Depressive Disorders
Mulsant, B. H., Kastango, K. B., Rosen, J., Stone, R. A., Mazumdar, S., & Pollock, B. G. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.9.1598 · Cited by 52
Rutherford, B. R., Sneed, J. R., Tandler, J. M., Rindskopf, D., Peterson, B. S., & Roose, S. P. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.04.004 · Cited by 51
Self-citationA randomized, prospective pilot study of patient expectancy and antidepressant outcome
Rutherford, B. R., Marcus, S. M., Wang, P., Sneed, J. R., Pelton, G., Devanand, D., Duan, N., & Roose, S. P. (2013) · Psychological Medicine · doi:10.1017/s0033291712001882 · Cited by 43
Self-citationCressey, D. (2011) · Nature · doi:10.1038/news.2011.367 · Cited by 30
Stettin, G., Yao, J., Verbrugge, R. R., & Aubert, R. E. (2006) · PubMed · Cited by 30
Is it Easier to Find What You Are Looking for if You Think You Know What it Looks Like?
Mundt, J. C., Greist, J. H., Jefferson, J. W., Katzelnick, D. J., DeBrota, D. J., Chappell, P. B., & Modell, J. G. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3180387820 · Cited by 29
Rater bias in a blinded randomized placebo-controlled psychiatry trial
Marcus, S. M., Gorman, J. M., Tu, X. M., Gibbons, R. D., Barlow, D. H., Woods, S. W., & Shear, M. K. (2005) · Statistics in Medicine · doi:10.1002/sim.2405 · Cited by 16
Antidepressant Clinical Trials and Subject Recruitment: Just Who Are Symptomatic Volunteers?
Brody, B. D., Leon, A. C., & Kocsis, J. H. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11060864 · Cited by 16
Dr, D., Vahia, V., & Mp, B. (1978) · PubMed · Cited by 16
Research works printed but not linked: 8
- Hooper M, Amsterdam JD: Do clinical trials reflect drug potential? A review of FDA evaluation of new antidepressants, in 39th Annual Meeting Abstracts of Poster Presentations, New Clinical Drug Evaluation Unit Program, 1999
- World Health Organization, 2004, The World Health Report 2004: Changing History, Annex Table 3: Burden of Disease in DALYs by Cause, Sex, and Mortality Stratum in WHO Regions, Estimates for 2002
- Bass MJ, 1986, J Fam Pract, 23, 43
- Stettin GD, 2006, Am J Manag Care, 12, 453
- 10.1037/0022-006X.60.5.664 · DOI · Paper page
- 10.1001/jama.1984.03350060032024 · DOI · Paper page
- Liberman RP, 1967, Neuropsychopharmacology, 5, 557
- Doongaji DR, 1978, J Postgrad Med, 24, 147
Cited by
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa068 · Cited by 418
“There is a well-known and substantial placebo response in antidepressant clinical trials due in large part to patient expectations and the intensity of therapeutic contacts (Rutherford and Roose, 2013; Leuchter et al., 2014).”
BackgroundCipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · Focus · doi:10.1176/appi.focus.16407 · Cited by 328
Motter, J. N., Pimontel, M. A., Rindskopf, D., Devanand, D. P., Doraiswamy, P. M., & Sneed, J. R. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.09.022 · Cited by 303
Blinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324
Metadata
- Authors
- Rutherford, B. R., & Roose, S. P.
- Affiliations
- New York State Psychiatric Institute (US)
- ORCID
- Rutherford, Bret R.
- Venue
- American Journal of Psychiatry
- Published
- 2013-07
- Volume
- 170
- Issue
- 7
- Pages
- 723-733
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC3628961
- OpenAlex
- W2147111327
- Cited by
- 268
- References
- 63
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 16 · 2023: 15 · 2022: 18 · 2021: 23 · 2020: 18 · 2019: 27 · 2018: 23 · 2017: 26 · 2016: 10 · 2015: 28 · 2014: 30 · 2013: 4
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (K23MH085236, T32MH015144)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- placebo response, antidepressants, major depressive disorder, clinical trial design, therapeutic contact, depression treatment, antidepressant efficacy
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Humans, Models, Psychological, Placebo Effect, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.